InflaRx N.V.
Business
InflaRx N.V. is a biopharmaceutical company discovering, developing, and commercializing complement-system inhibitors targeting C5a and its receptor C5aR to treat autoimmune and inflammatory diseases. Its lead product candidates are izicopan, an oral small-molecule C5aR antagonist in Phase 2a development for hidradenitis suppurativa and chronic spontaneous urticaria, and vilobelimab, an intravenous monoclonal antibody against C5a with an Emergency Use Authorization and European marketing authorization for severe COVID-19–induced acute respiratory distress syndrome. The company operates across two primary therapeutic modalities—antibody-based and small-molecule inhibition of the C5a/C5aR signaling axis—for neutrophil-driven and complement-mediated inflammatory conditions.
Summary from 20-F filed 2026-03-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-45.60M |
| Total assets | $55.22M |
| Total liabilities | $13.66M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is InflaRx N.V.'s CIK number?
InflaRx N.V.'s SEC CIK number is 0001708688 (1708688). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find InflaRx N.V.'s SEC filings?
All of InflaRx N.V.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.